English

COMMUNIQUÉ FROM EXTRAORDINARY GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL) HELD ON 21 APRIL 2023

Report this content

Prostatype Genomics AB (publ), listed on the Nasdaq First North Growth Market, held an extraordinary general meeting today on 21 April 2023, whereby the following decisions were made.

In accordance with previously published information, the board decided on a preferential share issue on 22 March 2023, subject to the subsequent approval of the extraordinary general meeting. The general meeting has today resolved to approve the board's decision on the preferential share issue in accordance with the below.

  • One (1) current share in Prostatype Genomics held on the record date on 25 April 2023 entitles to one (1) subscription right. One (1) subscription right entitles to subscription of six (6) newly issued shares.
  • The subscription price is SEK 0.25 per share. Payment shall be made in cash.
  • Through the preferential share issue, Prostatype Genomics could be provided with approximately MSEK 34.3 before any costs of the share issue, which are estimated to amount to MSEK 2.8.
  • Subscription shall be made during the period 27 April – 11 May 2023.
  • Subscription rights that are not exercised during the subscription period become invalid and lose their value. Trading in subscription rights is planned to take place on Nasdaq Premier First North Growth Market during the period 27 April to 8 May 2023.
  • If fully subscribed, the preferential share issue entails an increase in the Company´s share capital of not more than SEK 8,229,418.92, which corresponds to 137,156,982 shares and a maximum dilution of 85.7 percent.

The preferential share issue is guaranteed to 70 percent through guarantee undertakings from current and external investors.

In order to enable the preferential share issue, the general meeting resolved to change the articles of association by increasing the intervals for share capital and number of shares in accordance with the board's proposal. The new articles of association therefore read as follows.

§ 4 Share capital

The share capital shall be not less than SEK 6,000,000 and not more than SEK 24,000,000.

§ 5 Number of shares

The number of shares shall be not less than 100,000,000 and not more than 400,000,000.

The meeting also decided to approve the board's proposal to, on one or more occasions during the time until the next annual general meeting, decide to increase the company's share capital within the limits of the articles of association. The authorization may only be used to issue shares to those who acted as guarantors in the above-mentioned issue.

For further information, please contact:
Fredrik Persson, CEO Prostatype Genomics AB, tel. 073-0497701, email: fredrik.persson@prostatypegenomics.com.

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Subscribe